Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)
Phase of Trial: Phase IV
Latest Information Update: 31 Mar 2016
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TYCO
- Sponsors GlaxoSmithKline
- 25 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.
- 21 Apr 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.